Nature重磅：发现抗衰老新靶点，无需清除衰老细胞，减轻炎症并延长健康寿命

TL;DR - A Nature paper (published 2026-07-29, Mayo Clinic + Sanford Burnham Prebys) reports that mitochondrial metabolism and epigenetic regulation jointly drive the senescence-associated secretory phenotype (SASP), identifying the mitochondrial citrate transporter SLC25A1 as a druggable target that suppresses senescence-driven inflammation without clearing senescent cells. Note: this item is biomedical research with no AI/ML component.

• Mechanism: in senescent cells the mitochondrial pyruvate–citrate–acetyl-CoA axis is upregulated, raising acetyl-CoA availability that fuels histone acetylation at SASP gene loci; mtDNA/cGAS-STING signaling activates inflammatory transcription factors, but efficient SASP transcription still requires sufficient acetyl-CoA.
• Target: inhibiting SLC25A1 lowers histone acetylation and chromatin accessibility at SASP loci, limiting the inflammatory program.
• In vivo: SLC25A1 inhibition selectively dampened SASP-related inflammation in aged mice and extended healthspan without reversing/eliminating senescence — a shift away from the classic senolytic "clear the zombie cells" strategy.
• Framing: the authors describe a "mitochondrial metabolic checkpoint" that gates epigenetic execution of innate immune signaling. Paper: https://www.nature.com/articles/s41586-026-10791-2